Delisting risk removed for now, but the stock remains a micro-cap biotech with no disclosed revenue or near-term catalysts. Monitor the next 10-Q for cash runway and pipeline updates — the compliance resolution does not change the fundamental business outlook.
Price Chart
Executive Summary
GT Biopharma regained compliance with Nasdaq's $1.00 minimum bid price requirement after its common stock closed above $1.00 for at least ten consecutive business days, removing the immediate delisting risk that had been pending since November 2025. This is a procedural compliance update with no financial data or business catalyst — the stock remains a micro-cap biotech with no disclosed revenue or pipeline milestones.
Key Facts
- Company received Nasdaq deficiency notice on November 20, 2025 for bid price below $1.00 for 30 consecutive days
- Granted 180-day extension until November 16, 2026 to regain compliance
- On September 22, 2026, Nasdaq confirmed compliance after stock closed above $1.00 for at least 10 consecutive business days
- No financial statements, revenue figures, or operating metrics disclosed in this filing
Financial Impact
No financial impact — compliance regained with no monetary penalty or operational change
Risk Factors
- Stock could fall back below $1.00 and face renewed delisting risk
- No disclosed revenue, pipeline progress, or financing — continued going-concern risk
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-044309 |
| Document: 0001493152-26-044309-index-headers.html | 0001493152-26-044309 |
| Document: 0001493152-26-044309-index.html | 0001493152-26-044309 |
| Document: 0001493152-26-044309.txt | 0001493152-26-044309 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 6d ago | EFFECT | $5.41 | awaiting T+5 | — | $5.57 (−2.87%) |
Oct 13, 2026 13d ago | DEF 14A | $6.21 $5.41 | ▲ +12.88% | ▲ +13.34% | $5.57 (+10.39%) |
Oct 9, 2026 17d ago | S-1 | $6.80 $6.69 | ▲ +1.62% | ▲ +0.12% | $5.57 (+18.16%) |
Sep 25, 2026 4w ago | 8-K | $6.80 $6.16 | ▼ −9.41% | ▼ −10.62% | $5.57 (−18.16%) |
Sep 15, 2026 6w ago | 8-K | $9.00 $7.16 | ▲ +20.44% | ▲ +21.26% | $5.57 (+38.17%) |
Sep 3, 2026 7w ago | 8-K | $0.2524 $8.61 | ▲ +3311.25% | ▲ +3312.40% | $5.57 (+2104.83%) |
Aug 14, 2026 10w ago | Press Release | $0.2960 $0.2886 | ▲ +2.50% | ▲ +1.13% | $5.57 (−1780.07%) |
May 22, 2026 22w ago | 8-K | $0.4400 $0.4420 | ▼ −0.45% | ▲ +1.22% | $5.57 (−1164.77%) |
Apr 30, 2026 25w ago | S-1 | $0.3430 $0.3750 | ▼ −9.33% | ▼ −6.98% | $5.57 (−1522.45%) |
Apr 7, 2026 29w ago | 8-K | $0.4130 $0.3890 | ▼ −5.81% | ▼ −11.14% | $5.57 (+1247.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers